Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc 1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc 1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zeng Sheng¹²,Zhang Jingran¹²³,Sun Mingwei⁴,Zhang Xiaofei⁴⁵⁶,Cook Gregory M.⁷⁸,Zhang Tianyu¹²⁶^ORCID

Affiliation:

1. State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

2. Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

3. School of Life Sciences, University of Science and Technology of China, Hefei, China

4. Center for Cell Lineage and Atlas (CCLA), Bioland Laboratory (Guangzhou Regenerative Medicine and Health Guangdong Laboratory), Guangzhou, China

5. CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

6. University of Chinese Academy of Sciences, Beijing, China

7. Department of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand

8. Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Auckland, New Zealand

Abstract

Mycobacterium tuberculosis , the causative agent of human tuberculosis, harbors a branched electron transport chain, preventing the bactericidal action of cytochrome bc 1 inhibitors (e.g., TB47). Here, we investigated, using luminescent mycobacterial strains, the in vitro combination activity of cytochrome bc 1 inhibitors and nitric oxide (NO) donors including pretomanid (PMD) and explored the mechanisms of combination activity.

Funder

National Mega-project of China for Innovative Drugs

Health Research Council of New Zealand-NSFC Biomedical Collaboration Fund

Department of Science and Technology of Guangdong Province

China Postdoctoral Science Foundation

Chinese Academy of Sciences

National Natural Science Foundation of China

State Key Laboratory of Respiratory Disease

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology